Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Biogen announces first patient treated with higher dose SPINRAZA in DEVOTE study » 07:50
04/02/20
04/02
07:50
04/02/20
07:50
BIIB

Biogen

$293.79 /

-22.59 (-7.14%)

Biogen announced that the…

Biogen announced that the first patient has been treated in the global clinical study, DEVOTE. The study is designed to evaluate the safety, tolerability and potential for even greater efficacy of SPINRAZA when administered at a higher dose than currently approved for the treatment of spinal muscular atrophy. The Phase 2/3 randomized, controlled, dose-escalating study will be conducted at approximately 50 sites around the world and aims to enroll individuals of all ages with SMA. The three-part study will include an open-label safety evaluation cohort and a pivotal, double-blind, active control randomized treatment cohort followed by an open-label treatment cohort. After the safety evaluation cohort completes, the pivotal cohort will begin and include a treatment group receiving two loading doses of 50 milligrams 14 days apart, followed by a maintenance dose of 28 mg every four months. A second treatment group will receive the current U.S. Food and Drug Administration-approved administration of SPINRAZA, which is four loading doses with 12 mg maintenance doses every four months. The third cohort will be an open-label evaluation to assess the safety and tolerability of transitioning patients from the currently approved dose of SPINRAZA to the higher dose being tested in the study.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Initiation
Biogen initiated with a Peer Perform at Wolfe Research » 09:32
03/31/20
03/31
09:32
03/31/20
09:32
BIIB

Biogen

/

+

Wolfe Research analyst…

Wolfe Research analyst Tim Anderson initiated coverage of Biogen with a Peer Perform rating and $331 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Doctor survey shows 'massive' near-term COVID disruption, says Piper Sandler » 05:46
03/26/20
03/26
05:46
03/26/20
05:46
ABBV

AbbVie

$67.81 /

+0.04 (+0.06%)

, AMGN

Amgen

$193.12 /

-9.3 (-4.59%)

, BHC

Bausch Health

$15.76 /

+0.835 (+5.60%)

, BIIB

Biogen

$284.91 /

+8.72 (+3.16%)

, REGN

Regeneron

$428.58 /

-20.79 (-4.63%)

Doctors project…

Doctors project "massive disruption" on patient and prescribing trends, as well as clinical trial conduct, across neurology, nephrology, dermatology, rheumatology, gastroenterology and primary care from the COVID-19 outbreak, Piper Sandler analyst Christopher Raymond tells investors in a research note, citing a survey done by Spherix Global Insights. Specifically, everyone is seeing impact but dermatology maybe more so than others and renal patients remain most "at risk," adds the analyst. Across Piper's coverage, the key commercial franchises that appear "deleteriously impacted" are AbbVie's (ABBV) Humira, Skyrizi and Rinvoq, Amgen's (AMGN) Enbrel and renal franchise, Bausch Health's (BHC) Siliq and Duobrii, and Biogen's (BIIB) Tecfidera and Tysabri. Conversely, agents that could benefit from the disruption include Amgen's Otezla and Regeneron's (REGN) Kevzara, Raymond points out. The analyst says that while Piper is not changing estimates at this time, the "feedback is striking nonetheless."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Vir proceeding with two clinical development candidates for COVID-19 » 08:10
03/25/20
03/25
08:10
03/25/20
08:10
VIR

Vir Biotechnology

$31.99 /

-4.38 (-12.04%)

, BIIB

Biogen

$276.19 /

+6.85 (+2.54%)

, ALNY

Alnylam

$99.97 /

+0.43 (+0.43%)

Vir Biotechnology (VIR)…

Vir Biotechnology (VIR) announced that it has identified multiple human monoclonal antibody development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19. In an effort to save time, Vir's lead development candidate was transferred at-risk to WuXi Biologics and Biogen Inc. (BIIB) several weeks ago, and Vir anticipates that human trials can begin within 3-5 months. The ability of this antibody to neutralize the SARS-CoV-2 live virus has been confirmed in two separate laboratories. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 indicating that the epitope is highly conserved. Vir believes that the conservation of this epitope will make it more difficult for escape mutants to develop. Vir has engineered the Fc region of our lead development candidate in the following ways: A half-life extending alteration to potentially extend the time over which the antibody provides protection; and A second alteration that increases short-term potency, and in animal models leads to the generation of protective CD8+ T cells that may provide long-term immunity. This alteration gives the antibody the potential to function prophylactically, therapeutically, and to be able to induce long-term immunity. The lead development candidate is being produced with and without the vaccinal mutation, and Vir intends to move both versions into human testing. In addition, Vir has identified additional antibodies that bind to different sites, and therefore have the potential to be used in combination with the lead development candidate. The company is continuing its search for additional antibodies from survivors of SARS-CoV-2, SARS-CoV-1, and other coronaviruses. These antibodies may also be candidates to address the ongoing COVID-19 pandemic as well as coronavirus outbreaks that may occur in the future. Vir's long-term goal is to identify pan-coronavirus antibodies that could be effective against most or all coronavirus outbreaks. Vir has used this same approach in the discovery and development of VIR-2482, a pan-influenza A antibody that the company is developing for the prevention of influenza A. Vir intends to examine the potential applicability of its antibodies in four use cases: Prevention of disease: prophylaxis in health care workers or other individuals at high risk of becoming infected as well as prophylaxis for those at high risk of severe disease or death, such as the elderly with co-morbidities; Prevention of progression to severe disease: treatment of SARS-CoV-2 infected patients during the early phases of infection prior to onset of severe respiratory distress; Treatment of severe disease: treatment of SARS-CoV-2 infected patients with severe respiratory distress or other systemic illnesses; Development of vaccines: understanding the epitopes that lead to effective neutralization can aid in the development of effective vaccines. Vir is taking multiple approaches to identify additional potential therapies for SARS-CoV-2. In addition to antibodies, the company is working with Alnylam Pharmaceuticals (ALNY) to develop potential RNAi therapeutics and using its Innate Immunity Platform that applies cutting-edge genomic technologies to explore ways to interrupt the disease process using small molecules.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines » 11:45
03/20/20
03/20
11:45
03/20/20
11:45
INO

Inovio

$6.67 /

+0.2 (+3.09%)

, MRNA

Moderna

$28.60 /

+0.5 (+1.78%)

, NVAX

Novavax

$9.99 /

-1.59 (-13.73%)

, BNTX

BioNTech

$45.15 /

-13.95 (-23.60%)

, APDN

Applied DNA Sciences

$4.73 /

-0.87 (-15.54%)

, ABBV

AbbVie

$68.68 /

-2.43 (-3.42%)

, GSK

GlaxoSmithKline

$33.96 /

+0.37 (+1.10%)

, TNXP

Tonix Pharmaceuticals

$0.95 /

+0.3953 (+71.30%)

, GILD

Gilead

$77.07 /

-1.44 (-1.83%)

, JNJ

Johnson & Johnson

$123.15 /

-3.88 (-3.05%)

, SNY

Sanofi

$39.46 /

-1.2 (-2.95%)

, PFE

Pfizer

$29.51 /

-0.9 (-2.96%)

, VIR

Vir Biotechnology

$38.80 /

-3.99 (-9.32%)

, REGN

Regeneron

$470.00 /

-21.82 (-4.44%)

, BIIB

Biogen

$289.32 /

+0.93 (+0.32%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Shares of Inovio…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Sangamo call volume above normal and directionally bullish » 10:45
03/20/20
03/20
10:45
03/20/20
10:45
SGMO

Sangamo

$6.51 /

+0.39 (+6.37%)

Bullish option flow…

Bullish option flow detected in Sangamo with 1,004 calls trading, 1.2x expected, and implied vol increasing over 37 points to 115.54%. Apr-20 6 calls and Mar-20 6 calls are the most active options, with total volume in those strikes near 750 contracts. The Put/Call Ratio is 0.07. Earnings are expected on May 6th.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
COVID-19 drug seen as possible this year, vaccine in 2021 as crisis continues » 10:34
03/18/20
03/18
10:34
03/18/20
10:34
GILD

Gilead

$77.65 /

+3.23 (+4.34%)

, MRNA

Moderna

$29.37 /

+1.11 (+3.93%)

, ABBV

AbbVie

$70.39 /

-2.51 (-3.44%)

, JNJ

Johnson & Johnson

$133.65 /

-2.8 (-2.05%)

, SNY

Sanofi

$40.50 /

-3.11 (-7.13%)

, BNTX

BioNTech

$95.81 /

+29.71 (+44.95%)

, PFE

Pfizer

$31.88 /

-0.16 (-0.50%)

, NVAX

Novavax

$10.72 /

+1.27 (+13.44%)

, BIIB

Biogen

$301.06 /

-4.78 (-1.56%)

, REGN

Regeneron

$488.00 /

-4.5 (-0.91%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$34.58 /

-2.19 (-5.96%)

, VIR

Vir Biotechnology

$51.25 /

+1.26 (+2.52%)

As SARS-CoV-2, the virus…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biotechnology analysts to hold an analyst/industry conference call » 11:25
03/17/20
03/17
11:25
03/17/20
11:25
ALNY

Alnylam

$101.13 /

+3.04 (+3.10%)

, BIIB

Biogen

$304.25 /

+23.5 (+8.37%)

, GILD

Gilead

$73.70 /

+4.695 (+6.80%)

, INO

Inovio

$7.00 /

+0.89 (+14.57%)

, MRNA

Moderna

$31.29 /

+4.89 (+18.52%)

, OPK

Opko Health

$1.69 /

-0.06 (-3.44%)

, REGN

Regeneron

$506.00 /

+64.45 (+14.60%)

Biotech Analysts…

Biotech Analysts Tenthoff, Amsellem and Brill, along with Key Opinion Leader Dr. Dan Chen, CMO of IgM Biosciences provides a broad overview on SARS-CoV-2, as well on the current situation, best/worse case scenarios and COVID-19 therapies and vaccines currently in development on an Analyst/Industry conference call to be held on March 17 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biotechnology analysts to hold an analyst/industry conference call » 04:55
03/17/20
03/17
04:55
03/17/20
04:55
ALNY

Alnylam

$98.09 /

-3.06 (-3.03%)

, BIIB

Biogen

$280.75 /

-25.12 (-8.21%)

, GILD

Gilead

$69.00 /

-1.69 (-2.39%)

, INO

Inovio

$6.11 /

-0.73 (-10.67%)

, MRNA

Moderna

$26.40 /

+5.1 (+23.94%)

, OPK

Opko Health

$1.70 /

-0.17 (-9.09%)

, REGN

Regeneron

$441.55 /

-22.24 (-4.80%)

Biotech Analysts…

Biotech Analysts Tenthoff, Amsellem and Brill, along with Key Opinion Leader Dr. Dan Chen, CMO of IgM Biosciences provides a broad overview on SARS-CoV-2, as well on the current situation, best/worse case scenarios and COVID-19 therapies and vaccines currently in development on an Analyst/Industry conference call to be held on March 17 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biotechnology analysts to hold an analyst/industry conference call » 15:59
03/13/20
03/13
15:59
03/13/20
15:59
ALNY

Alnylam

$97.75 /

+4.68 (+5.03%)

, BIIB

Biogen

$297.04 /

+28.18 (+10.48%)

, GILD

Gilead

$69.91 /

+1.44 (+2.10%)

, INO

Inovio

$7.24 /

-2.175 (-23.11%)

, MRNA

Moderna

$20.16 /

-2.11 (-9.47%)

, OPK

Opko Health

$1.80 /

+0.38 (+26.86%)

, REGN

Regeneron

$452.18 /

+21.26 (+4.93%)

Biotech Analysts…

Biotech Analysts Tenthoff, Amsellem and Brill, along with Key Opinion Leader Dr. Dan Chen, CMO of IgM Biosciences provides a broad overview on SARS-CoV-2, as well on the current situation, best/worse case scenarios and COVID-19 therapies and vaccines currently in development on an Analyst/Industry conference call to be held on March 17 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.